» Articles » PMID: 21077101

Glycogen Hyperphosphorylation Underlies Lafora Body Formation

Overview
Journal Ann Neurol
Specialty Neurology
Date 2010 Nov 16
PMID 21077101
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Glycogen, the largest cytosolic macromolecule, acquires solubility, essential to its function, through extreme branching. Lafora bodies are aggregates of polyglucosan, a long, linear, poorly branched, and insoluble form of glycogen. Lafora bodies occupy vast numbers of neuronal dendrites and perikarya in Lafora disease in time-dependent fashion, leading to intractable and fatal progressive myoclonus epilepsy. Lafora disease is caused by deficiency of either the laforin glycogen phosphatase or the malin E3 ubiquitin ligase. The 2 leading hypotheses of Lafora body formation are: (1) increased glycogen synthase activity extends glycogen strands too rapidly to allow adequate branching, resulting in polyglucosans; and (2) increased glycogen phosphate leads to glycogen conformational change, unfolding, precipitation, and conversion to polyglucosan. Recently, it was shown that in the laforin phosphatase-deficient form of Lafora disease, there is no increase in glycogen synthase, but there is a dramatic increase in glycogen phosphate, with subsequent conversion of glycogen to polyglucosan. Here, we determine whether Lafora bodies in the malin ubiquitin ligase-deficient form of the disease are due to increased glycogen synthase or increased glycogen phosphate.

Methods: We generated malin-deficient mice and tested the 2 hypotheses.

Results: Malin-deficient mice precisely replicate the pathology of Lafora disease with Lafora body formation in skeletal muscle, liver, and brain, and in the latter in the pathognomonic perikaryal and dendritic locations. Glycogen synthase quantity and activity are unchanged. There is a highly significant increase in glycogen phosphate.

Interpretation: We identify a single common modification, glycogen hyperphosphorylation, as the root cause of Lafora body pathogenesis.

Citing Articles

Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease.

Nitschke S, Montalbano A, Whiting M, Smith B, Mukherjee-Roy N, Marchioni C EMBO J. 2025; 44(5):1379-1413.

PMID: 39806098 PMC: 11876434. DOI: 10.1038/s44318-024-00339-3.


Neuromuscular junction dysfunction in Lafora disease.

Shukla M, Chugh D, Ganesh S Dis Model Mech. 2024; 17(10).

PMID: 39301689 PMC: 11512103. DOI: 10.1242/dmm.050905.


Neurological glycogen storage diseases and emerging therapeutics.

Colpaert M, Singh P, Donohue K, Pires N, Fuller D, Corti M Neurotherapeutics. 2024; 21(5):e00446.

PMID: 39277505 PMC: 11581880. DOI: 10.1016/j.neurot.2024.e00446.


Clinicopathologic Dissociation: Robust Lafora Body Accumulation in Malin KO Mice Without Observable Changes in Home-Cage Behavior.

Krishnan V, Wu J, Mazumder A, Kamen J, Schirmer C, Adhyapak N J Comp Neurol. 2024; 532(7):e25660.

PMID: 39039998 PMC: 11370821. DOI: 10.1002/cne.25660.


Myofiber-type-dependent 'boulder' or 'multitudinous pebble' formations across distinct amylopectinoses.

Mitra S, Chen B, Shelton J, Nitschke S, Wu J, Covington L Acta Neuropathol. 2024; 147(1):46.

PMID: 38411740 DOI: 10.1007/s00401-024-02698-x.